246250 — SLS Bio Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for SLS Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,243	10,752	9,023	8,371	3,984
Cost of Revenue
Gross Profit	2,179	4,210	3,111	2,269	-1,937
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	7,816	8,328	7,992	8,084	8,089
Operating Profit	426	2,424	1,031	288	-4,105
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	259	2,225	1,057	354	-5,380
Provision for Income Taxes
Net Income After Taxes	57.9	2,826	1,434	336	-4,904
Net Income Before Extraordinary Items
Net Income	57.9	2,826	1,434	336	-4,904
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	57.9	2,826	1,434	336	-4,904
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.66	204	102	22	-326
Dividends per Share